How Analysts Rated Hutchison China MediTech Limited (LON:HCM) Last Week?

Out of 2 analysts covering Hutchison China Meditech Ltd (LON:HCM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Hutchison China Meditech Ltd has been the topic of 14 analyst reports since November 2, 2015 according to StockzIntelligence Inc. Panmure Gordon reinitiated the stock on September 16 with “Buy” rating. Below is a list of Hutchison China MediTech Limited (LON:HCM) latest ratings and price target changes.

16/09/2016 Broker: Panmure Gordon Rating: Buy New Target: GBX 2630.00 Reinitiate
03/08/2016 Broker: Beaufort Securities Rating: Buy Maintain
01/08/2016 Broker: Panmure Gordon Rating: Under Review Under Review
21/06/2016 Broker: Beaufort Securities Rating: Buy Maintain
20/06/2016 Broker: Panmure Gordon Rating: Under Review Under Review
16/05/2016 Broker: Beaufort Securities Rating: Buy Maintain
13/04/2016 Broker: Beaufort Securities Rating: Buy Maintain

Hutchison China MediTech Limited (LON:HCM) has declined 17.83% since February 26, 2016 and is downtrending. It has underperformed by 29.09% the S&P500.

Hutchison China MediTech Limited is a China-based, globally-focused healthcare group. The company has a market cap of 1.10 billion GBP. The Firm researches, develops, makes and sells pharmaceuticals and health-related consumer products. It currently has negative earnings. The Company’s Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment